Ikarian Capital’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Ikarian Capital’s Portfolio BXRX Stock Details BXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-74	Closed	-$3K	–	178
2022 Q2	$3K	Hold	74	–	–	﹤0.01%	137
2022 Q1	$4K	Buy	74 +6	+9%	+$1.11K	﹤0.01%	194
2021 Q4	$21K	Hold	68	–	–	﹤0.01%	180
2021 Q3	$53K	Sell	68 -3	-4%	-$2.61K	﹤0.01%	209
2021 Q2	$76K	Hold	71	–	–	0.01%	210
2021 Q1	$129K	Hold	71	–	–	﹤0.01%	280
2020 Q4	$101K	Hold	71	–	–	﹤0.01%	214
2020 Q3	$277K	Hold	71	–	–	0.02%	150
2020 Q2	$415K	Sell	71 -54	-43%	-$259K	0.03%	138
2020 Q1	$434K	Buy	+125	New	+$1.18M	0.03%	137

Other funds holding BXRX

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital's BXRX Position: Q3 2022 in Review

Ikarian Capital sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q3 2022, closing a stake of 74 shares — an estimated $3K sold.

Ikarian Capital first reported a position in BXRX in Q1 2020 and held it in 10 quarters. The position peaked at $434K in Q1 2020. 20 funds tracked by Wall St. Rank hold BXRX as of Q3 2022.

Ikarian Capital reported no remaining Baudax Bio, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Ikarian Capital sold 74 Baudax Bio, Inc. Common Stock shares in Q3 2022, an estimated $3K.
Ikarian Capital first reported a position in Baudax Bio, Inc. Common Stock in Q1 2020 and held it in 10 quarters.
Ikarian Capital's Baudax Bio, Inc. Common Stock position peaked at $434K in Q1 2020.
20 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.